All In Biotech

Drug Trial Radar · NCT05074810

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

Apr 12, 2022

Primary completion

Jun 2026

Study completion Apr 2027

Sponsor

Lead sponsor
Verastem, Inc.Industry
Sponsor type
Industry
Collaborators
Amgen
First posted
Oct 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.

Conditions

  • Non Small Cell Lung Cancer
  • KRAS Activating Mutation

Interventions

  • avutometinib and sotorasibDrug

    The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion

  • avutometinib and sotorasib and defactinibDrug

    The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: To determine RP2D for avutometinib in combination with sotorasib and the Alt-RP2D for avutometinib in combination with sotorasib and defactinibTime frame: From start of treatment to confirmation of RP2D; 28 days
  2. Part B: To determine the efficacy of the RP2D and/or Alt-RP2D identified from Part ATime frame: From start of treatment to confirmation of response; 16 weeks

Locations

35 sites in 6 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Center, LLP

    Boulder, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute,

    Washington D.C., District of Columbia

  • Illinois Cancer Specialists

    Arlington Heights, Illinois

  • Maryland Oncology & Hematology, P.A.

    Rockville, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Minnesota Oncology Hematology, P.A

    Woodbury, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio

  • Ohio State University Brain and Spine Hospital

    Columbus, Ohio

  • Consultants in Medical Oncology & Hematology

    Broomall, Pennsylvania

  • Alliance Cancer Specialists,

    Horsham, Pennsylvania

  • Texas Oncology

    Austin, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Texas Oncology - Fort Worth Cancer Center

    Fort Worth, Texas

  • Texas Oncology

    Longview, Texas

  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

    Blacksburg, Virginia

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Northwest Cancer Specialists

    Vancouver, Washington

  • University Hospital Gent

    Ghent, Belgium

  • CHU de Liège

    Liège, Belgium

  • CHRU of Lille

    Lille, France

  • Hôpital Cochin

    Paris, France

  • Hôpital Foch

    Suresnes, France

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Erasmus MC

    Rotterdam, Netherlands

  • Hospital Teresa Herrera (C.H.U.A.C)

    A Coruña, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Universitario Virgen De La Victoria

    Málaga, Spain

  • Hospital Universitario Virgen de la Macarena

    Seville, Spain

  • University of Leicester

    Leicester, United Kingdom

  • Royal Marsden Hospital

    London, United Kingdom

  • Royal Marsden Hospital

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.